Skip to main content
. 2015 May 11;33(18):2021–2027. doi: 10.1200/JCO.2014.60.1963

Fig 1.

Fig 1.

Observed rates of cognitive impairment in group of patients with prostate cancer receiving androgen-deprivation therapy (ADT+) and control group. Criteria for impaired cognitive performance: (A) scoring ≥ 1.5 standard deviations (SDs) below published norms on ≥ two tests or 2.0 SDs below published norms on ≥ one test (group differences in change over time P = .05); (B) scoring ≥ 2.0 SDs below published norms on ≥ one test (group differences in change over time P = .01).